ATM and neoplasm: In ATM-deficient cancer cells, the ATR inhibitor ceralasertib combined with the DNA crosslinker, PBD SG-3199, activated dendritic cells in a STING-IFN-dependent manner, externally fortifying tumor immunogenicity [165].